Lu Yang

Lu Yang

Auto-generated profile, based on publicly available information

Lu Yang

Department of Radiation Oncology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYutian Zou
Yutian Zou
Shaoquan ZhengShaoquan Zheng
Shaoquan Zheng
XXXinhua Xie
Xinhua Xie
FYFeng Ye
Feng Ye
XHXiaoqian Hu
Xiaoqian Hu
XXXiaoming Xie
Xiaoming Xie
Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe2+ efflux efficiency via the β-catenin/TCF4-SLC7A11/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer.

31 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
Yuhui TangYuhui Tang
Yuhui Tang
WTWenwen Tian
Wenwen Tian
JXJindong Xie
Jindong Xie
YZYutian Zou
Yutian Zou
ZWZehao Wang
Zehao Wang
LYLu Yang
Lu Yang
Fatty acid metabolism has been deciphered to augment tumorigenesis and disease progression in addition to therapy resistance via strengthened lipid synthesis, storage, and catabolism. Breast cancer is strongly associated with the biological function of fatty acid metabolism owing to the abundant presence of adipocytes in breast tissue. It has been unraveled that tumor cells exhibit considerable plasticity based on fatty acid metabolism, responding to extra-tumoral and a range of metabolic signals, in which tumor microenvironment plays a pivotal role. However, the prognostic significance of fatty acid metabolism in breast cancer remains to be further investigated. Alongside these insights, we retrieved 269 reliable fatty acid metabolism-related genes (FMGs) and identified the landscape of copy number variations and expression level among those genes. Additionally, 11 overall survival-related FMGs were clarified by univariate Cox hazards regression analysis in The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases. Subsequently, a prognostic signature based on 6 overall survival (OS)-related FMGs was generated using Lasso Cox hazards regression analysis in TCGA dataset and was validated in two external cohorts. The correlation between the signature and several essential clinical parameters, including T, N, and PAM50 subtypes, was unveiled by comparing the accumulating signature value in various degrees. Furthermore, an optimal nomogram incorporating the signature, age, and American Joint Committee on Cancer (AJCC) stage was constructed, and the discrimination was verified by C-index, the calibration curve, and the decision curve analysis. The underlying implications for immune checkpoints inhibitors, the landscape of tumor immune microenvironment, and the predictive significance in therapy resistance to diverse strategies were depicted ultimately. In conclusion, our findings indicate the potential prognostic connotation of fatty acid metabolism in breast cancer, supporting novel insights into breast cancer patients’ prognosis and administrating effective immunotherapy.

14 July 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
HSHengwen Sun
Hengwen Sun
WHWei Huang
Wei Huang
FJFei Ji
Fei Ji
YPYi Pan
Yi Pan
LYLu Yang
Lu Yang
Background: Metastases are the main cause of breast cancer-related deaths. Breast cancer has a more aggressive phenotype and less favorable prognosis in young females than in older females. In this study, we aimed to compare the metastatic patterns, survival outcomes and tumor immune microenvironment of young and non-young breast cancer patients.Methods: Patients with a diagnosis of breast cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. The significance of young age (≤40 years) in the metastatic profile and prognosis of breast cancer was investigated. The transciptome expression data were acquired from The Cancer Genome Atlas (TCGA) database. And the differentially expressed genes (DEGs) and primarily enriched function pathways were identified by comparing between young and non-young breast cancer samples, and tumor immune infiltrating cell types in the tumor microenvironment were compared.Results: A total of 281,829 female breast cancer patients were included in SEER: 18,331 young (6.5%) and 263,498 non-young (93.5%) women. The metastatic rates of bone, liver and distant lymph nodes (DLNs) in the young cohort were significantly higher than those in the non-young cohort. The most frequent two-site metastatic combination was bone and liver (0.61%) in the young cohort, whereas it was bone and lung (0.32%) in the non-young cohort. Breast cancer-specific survival (BCSS) was significantly shortened among those in the young cohort compared with those in the non-young cohort (p < 0.001). Young age was associated with significantly shorter BCSS only among patients with HR+/HER2- tumors (p < 0.001). The enriched biological pathways based on DEGs between two cohorts were related to the regulation of immune response and several metabolic processes. M2 macrophages were significantly abundant in non-young breast cancer than young breast cancer.Conclusion: Young and non-young breast cancer patients present with different metastatic patterns. Young age is a negative prognostic factor, particularly for HR+/HER2- breast cancer. The differences in metastatic patterns between young and non-young cohorts should be taken into account in the clinical management of metastatic breast cancer. The young breast cancer patients may gain better response to immunotherapy due to immune activated TME than non-young breast cancer.

11 August 2026 in Cancer Research
Verified
Journal Article
Closed access
JZJunsheng Zhang
Junsheng Zhang
NLNing Li
Ning Li
RLRongrong Li
Rongrong Li
YCYitian Chen
Yitian Chen
CACharles R. Ashby
Charles R. Ashby
LYLu Yang
Lu Yang
Fasting-mimicking diets (FMD) have been reported to increase the antitumor efficacy in preclinical studies in various cancers. FMD can affect the tumor microenvironment (TME), and elucidating the mechanisms and cells mediating the effects of FMD may uncover combination treatment strategies. Here, we performed single-cell transcriptomic sequencing to characterize the TME changes induced by FMD intervention in a mouse model of spontaneous breast cancer. The sequencing data indicated that FMD suppressed tumor cell stemness, promoted apoptosis, and increased the infiltration of innate and adaptive immune cells, especially natural killer (NK) cells and effector CD8+ T cells. Importantly, FMD induced phenotypic reprogramming of cancer-associated fibroblasts (CAF), leading to a decrease in the immunosuppressive inflammatory CAF (iCAF) subset. Mechanistically, FMD decreased platelet-derived growth factor C (PDGFC) secretion in tumor cells by reducing glucose levels and inhibiting glycolysis to reprogram CAFs. PDGFC increased the activation of the JAK–STAT3 pathway, which induced iCAF differentiation. Combining FMD with PDGF receptor (PDGFR) inhibitors increased the efficacy of anti–PD-L1 immunotherapy in vivo. Overall, this study reveals a mechanism of metabolic–immune rewiring through which FMD suppresses tumor progression, providing preliminary evidence for the potential of combination FMD-based strategies in breast cancer treatment. Significance: Fasting-mimicking diet blocks breast cancer cell-induced generation of immunosuppressive fibroblasts, thereby facilitating tumor infiltration of immune cells and stimulating antitumor immunity to sensitize breast cancer to immunotherapy.

1 August 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
NLNing Li
Ning Li
LFLi-Wen Feng
Li-Wen Feng
ZLZuo-Nong Li
Zuo-Nong Li
JWJin Wang
Jin Wang
LYLu Yang
Lu Yang
Purpose: Young age is an independent negative predictor of breast cancer (BC) survival and correlates with the risk of local recurrence and contralateral BC. We aimed to design an effective and comprehensive nomogram to predict prognosis in very young patients with curatively resected BC. Methods: Female patients with a diagnosis of BC aged ≤ 35 years at presentation were identified from the SEER database as a training cohort. The validation cohort consisted of 1002 consecutive women with BC aged ≤ 35 years that had received curative resection for BC at the Sun Yat-sen University Cancer Center. A nomogram was built based on the identified variables in multivariate Cox proportional hazards model. The performance of the nomogram was quantified using Harrell’s concordance index (C-index) and calibration curves. Results: Overall, 10,872 young female patients who underwent surgery for BC were enrolled in the training cohort, while 1002 very young female BC patients were identified as independent validation cohort. Eight covariables (age, race, grade; ER, PR, and HER2 status; T, and N stages) were identified and incorporated to construct a nomogram. The C-index values of the nomogram were 0.727 (95% CI: 0.714– 0.740) and 0.722 (95% CI: 0.666– 0.778) for OS in the training and validation cohorts, respectively. The calibration curves showed a high degree of agreement between the predicted and actual observed survival rates in both training and validation cohorts. The nomogram displayed good calibration and acceptable discrimination. Based on the TPS of the nomogram model for OS with the X-tile program, patients were divided into 3 risk groups, which were easily discriminated on survival analyses for OS. Conclusion: We have successfully constructed an effective nomogram to predict survival outcomes for young female patients with curatively resected BC, which may provide individual survival prediction to benefit prognosis evaluation and individualized therapy.

3 November 2026
Verified
Other
Open access
JZJunsheng Zhang
Junsheng Zhang
NLNing Li
Ning Li
RLRongrong Li
Rongrong Li
YCYitian Chen
Yitian Chen
CACharles R. Ashby
Charles R. Ashby
LYLu Yang
Lu Yang
Fasting-mimicking diets (FMD) have been reported to increase the antitumor efficacy in preclinical studies in various cancers. FMD can affect the tumor microenvironment (TME), and elucidating the mechanisms and cells mediating the effects of FMD may uncover combination treatment strategies. Here, we performed single-cell transcriptomic sequencing to characterize the TME changes induced by FMD intervention in a mouse model of spontaneous breast cancer. The sequencing data indicated that FMD suppressed tumor cell stemness, promoted apoptosis, and increased the infiltration of innate and adaptive immune cells, especially natural killer (NK) cells and effector CD8+ T cells. Importantly, FMD induced phenotypic reprogramming of cancer-associated fibroblasts (CAF), leading to a decrease in the immunosuppressive inflammatory CAF (iCAF) subset. Mechanistically, FMD decreased platelet-derived growth factor C (PDGFC) secretion in tumor cells by reducing glucose levels and inhibiting glycolysis to reprogram CAFs. PDGFC increased the activation of the JAK–STAT3 pathway, which induced iCAF differentiation. Combining FMD with PDGF receptor (PDGFR) inhibitors increased the efficacy of anti–PD-L1 immunotherapy in vivo. Overall, this study reveals a mechanism of metabolic–immune rewiring through which FMD suppresses tumor progression, providing preliminary evidence for the potential of combination FMD-based strategies in breast cancer treatment. Significance:Fasting-mimicking diet blocks breast cancer cell-induced generation of immunosuppressive fibroblasts, thereby facilitating tumor infiltration of immune cells and stimulating antitumor immunity to sensitize breast cancer to immunotherapy.